Impact of Induction Therapy Type
The most commonly immunosuppressant used was Basiliximab (57.2%,
n=4,886) followed by thymoglobulin (32.5%, n=2,775) (Supplementary
Table 3). A sub-analysis that evaluated patients who received induction
therapy with either Thymoglobulin or Basiliximab (n=7,661) indicated
that risk-adjusted odds were comparable between the type of induction
therapy for drug-treated rejection at 1-year, renal failure requiring
dialysis, and mortality at all time intervals (Supplementary Table 4)